| |
| |
|
| Insider
Information: |
Shanmugam Muthusamy |
| Relationship: |
HEAD OF R&D, COO-NOVIT... |
| City: |
Baudette |
| State: |
MN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,652 |
|
|
Indirect Shares
|
737,620 |
|
|
| Direct
Value |
$4,616,847 |
|
|
|
Indirect Value
|
$49,604,945 |
|
|
| Total
Shares |
806,272 |
|
|
| Total
Value |
$54,221,792 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
ANI Pharmaceuticals Inc |
ANIP |
HEAD OF R&D, COO-NOVIT... |
2024-05-20 |
68,652 |
2024-05-20 |
737,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-02-29 |
4 |
D |
$67.67 |
$75,926 |
D/D |
(1,122) |
68,652 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-08 |
4 |
AS |
$67.17 |
$671,700 |
I/I |
(10,000) |
832,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-07 |
4 |
AS |
$66.35 |
$1,000,890 |
I/I |
(15,085) |
842,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-15 |
4 |
AS |
$66.33 |
$491,771 |
I/I |
(7,414) |
825,206 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-16 |
4 |
AS |
$66.20 |
$386,211 |
I/I |
(5,834) |
819,372 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-15 |
4 |
AS |
$65.86 |
$978,021 |
I/I |
(14,850) |
767,770 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-06 |
4 |
AS |
$65.47 |
$970,396 |
I/I |
(14,822) |
857,705 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-17 |
4 |
AS |
$65.40 |
$622,608 |
I/I |
(9,520) |
809,852 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-03-05 |
4 |
AS |
$65.35 |
$659,578 |
I/I |
(10,093) |
872,527 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-19 |
4 |
AS |
$65.17 |
$1,095,443 |
I/I |
(16,809) |
782,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-04-18 |
4 |
AS |
$64.98 |
$677,287 |
I/I |
(10,423) |
799,429 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-16 |
4 |
AS |
$63.84 |
$1,050,743 |
I/I |
(16,459) |
751,311 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-29 |
4 |
S |
$63.37 |
$1,584,250 |
I/I |
(25,000) |
1,132,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-28 |
4 |
S |
$63.06 |
$1,576,500 |
I/I |
(25,000) |
1,157,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-15 |
4 |
AS |
$62.81 |
$1,020,160 |
I/I |
(16,242) |
1,116,378 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-17 |
4 |
AS |
$62.09 |
$362,357 |
I/I |
(5,836) |
745,475 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-05-20 |
4 |
AS |
$61.81 |
$794,568 |
I/I |
(12,855) |
732,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-18 |
4 |
AS |
$61.64 |
$519,317 |
I/I |
(8,425) |
1,107,953 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-15 |
4 |
AS |
$61.60 |
$1,361,976 |
I/I |
(22,110) |
1,182,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-19 |
4 |
AS |
$61.23 |
$1,551,140 |
I/I |
(25,333) |
1,082,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-14 |
4 |
AS |
$61.15 |
$1,705,474 |
I/I |
(27,890) |
1,204,730 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-17 |
4 |
AS |
$58.53 |
$512,606 |
I/I |
(8,758) |
1,048,862 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-16 |
4 |
AS |
$58.31 |
$761,704 |
I/I |
(13,063) |
1,057,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-18 |
4 |
AS |
$57.78 |
$360,663 |
I/I |
(6,242) |
1,042,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-13 |
4 |
AS |
$57.58 |
$687,332 |
I/I |
(11,937) |
1,070,683 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
